In Russia, the first batch of a drug against ankylosing spondylitis with the active ingredient seniprutug went into public circulation. The Biocad company collaborated with scientists from the Pirogov Russian National Research Medical University and the Institute of Bioorganic Chemistry, named after the academicians M. M., to develop the product. Shemyakin and Yu. A. Ovchinnikov.
Ankylosing spondylitis is a type of arthritis that causes inflammation in the joints and ligaments of the spine. It may also affect peripheral joints like the knees, ankles, and hips.
In May, Russian Health Minister Mikhail Murashko announced that the medication would be available for sale in approximately three months, specifically in August. Additionally, he announced the inclusion of seniprutug in the list of vital and essential medicines.
